MeiraGTx is a clinical‑stage genetic medicine company developing therapies for rare and common diseases. It leverages a riboswitch gene regulation platform that provides precise spatial and temporal control of transgene expression, expanding the range of conditions that can be treated with genetic medicines. The company also operates an end‑to‑end manufacturing ecosystem to streamline development and delivery of its bespoke gene‑based treatments.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic therapies are limited to rare inherited disorders and require high, uncontrolled doses of viral vectors, which can cause safety concerns and restrict treatment to specialized clinics. Additionally, delivering gene therapies to common diseases and achieving precise control over transgene expression in patients remains a major challenge.
Solution
MeiraGTx develops a riboswitch‑based gene regulation platform that enables dose‑responsive, oral‑small‑molecule control of transgene expression, providing spatial and temporal precision for both rare and prevalent indications. The platform is combined with optimized AAV capsids, promoters, and translational control elements to create potent, safe viral vectors. An in‑house, vertically integrated manufacturing ecosystem produces GMP‑grade vectors at commercial scale, ensuring consistent quality and rapid supply. This approach expands the therapeutic reach of genetic medicines to diseases such as Parkinson’s, radiation‑induced xerostomia, and multiple retinal dystrophies, while allowing clinicians to modulate dosing post‑administration.
Target Audience
Primary customers are pharmaceutical and biotech companies developing gene‑therapy programs, as well as clinical researchers seeking precise, controllable genetic treatments for rare and common diseases.
Features
- Riboswitch gene regulation that activates or suppresses transgene expression in response to orally administered small molecules
- Optimized AAV capsid and promoter designs for high potency and tissue‑specific delivery
- End‑to‑end GMP manufacturing capability, including two licensed viral vector production facilities and a dedicated QC suite
- Platform applicability across diverse indications, from neurodegenerative and ophthalmic disorders to metabolic peptide delivery and cell‑based therapies
- Ability to deliver low, localized vector doses, reducing systemic exposure and improving safety profiles